Bijoyesh Mookerjee

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

Georgina V. Long, Axel Hauschild, Mario Santinami et al. · New England Journal of Medicine · 2017 · 1.4K citations · Full text

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

Versus Dabrafenib, Val600 Braf-mutant Melanoma, Oncology +7

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

David Planchard, Egbert F. Smit, Harry J.M. Groen et al. · The Lancet Oncology · 2017 · 1.3K citations · Full text

Medicine, Pathology, Bronchial Neoplasm +5

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

Rajani Ravi, Bijoyesh Mookerjee, Zaver M. Bhujwalla et al. · PubMed · 2000 · 1.1K citations · Full text

Tumor Xenografts, Pathology, Cancer Biology +19

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α

Rajani Ravi, Bijoyesh Mookerjee, Zaver M. Bhujwalla et al. · Genes & Development · 2000 · 951 citations · Full text

Hypoxia-inducible Factor 1α, Cancer Biology, Redox Biology +18